Public Event Detail
Arbutus Biopharma earnings beat by $0.91, revenue topped estimates
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Historical observations only. No forecasts, recommendations, buy/sell ratings, or portfolio advice.
2026-05-13AAPLAppleAlpha Vantage Newsearnings
Event summary
Arbutus Biopharma (NASDAQ: ABUS) exceeded analyst expectations for its first-quarter earnings, reporting an EPS of $0.870 against an estimated $-0.040. The company's revenue also significantly topped estimates, coming in at $179.23M compared to the consensus of $400K. The stock has seen substantial growth over the past year, reflecting "good performance" according to InvestingPro.
Attached public signals
Observed outcomes
7d returnPending
30d returnPending
90d returnPending
Relative 90d returnPending